The Role of Platelet-Rich Fibrin (PRF) in the Prevention of Medication-Related Osteonecrosis of the Jaw (MRONJ)

Table 2

Clinical information of patients presenting MRONJ.

Data collected from MRONJ manifestations
Patients	#1	#2	#3	#4	#5
Age (years)	66	75	68	55	81
Gender	F	F	F	F	F
Risk factors	Smoking habits	x	Diabetes	x	x
Type of systemic disease	Osteoporosis	Oncological disease	Oncological disease	Oncological disease	Osteoporosis
Medication	Alendronate	Ibandronate		Ibandronate	Alendronate
Route of drug therapy	Oral	Intravenous	Oral	Intravenous	Oral
Duration of drug therapy (months)	88	43	62	69	55
Risk associated to CTX	High	High	High	High	High
MRONJ stage	2	2	2	2	2
MRONJ site	Anterior mandible	Anterior mandible	Posterior mandible	Posterior mandible	Anterior mandible
Number of tooth extracted	3	1	2	1	2
Manifestation of MRONJ after extraction (months)	2	4	3	4	5